Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.6310
-0.0170 (-2.62%)
Mar 20, 2026, 4:00 PM EDT - Market closed
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
|---|
Discovery and Development of Oral Recombinant Protein Vaccines | 237.26M | 28.70M | 7.38M | 107.00K | 892.00K | | | | | |
Discovery and Development of Oral Recombinant Protein Vaccines Growth | 726.68% | 288.94% | 6796.26% | -88.00% | -77.95% | | | | | |
| 237.26M | 28.70M | 7.38M | 107.00K | 892.00K | | | | | |
| 726.68% | 288.94% | 6796.26% | -88.00% | -77.95% | | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
|---|
| 237.26M | 28.70M | 7.38M | 107.00K | 892.00K | | | | | |
| 726.68% | 288.94% | 6796.26% | -88.00% | -77.95% | | | | | |
| 237.26M | 28.70M | 7.38M | 107.00K | 892.00K | | | | | |
| 726.68% | 288.94% | 6796.26% | -88.00% | -77.95% | | | | | |
Source: S&P Global Market Intelligence.